

Stuart M. Langbein

Partner

Washington, D.C.

Biography

Stuart Langbein brings a passion for health care to his office each day. He is renowned for his leadership in facilitating the market viability of new medical technologies, and knows how to develop and implement strategies that secure their coverage, coding, and reimbursement.

When clients work with Stuart, they quickly learn about the importance of being proactive. That's especially critical for organizations with new medical technologies; Stuart is often advising them long before they're granted Food and Drug Administration approval.

Stuart routinely works with a cross-section of medical technology organizations, including pharmaceutical, biological, and medical device companies; trade associations, and academic medical centers. He continues to build on his prior experience at the Centers for Medicare & Medicaid Services, as well as on his long-term relationships with many agency officials.

Stuart is a longstanding volunteer for the JDRF, an international organization focused on a cure for diabetes. He coordinates the Hogan Lovells Walk to Cure Diabetes team, and works on national government advocacy issues related to diabetes.

Representative experience

Secured coding and Medicare payment for new mammography technology.



Phone

+1 202 637 5744

Fax

+1 202 637 5910

Email

stuart.langbein@hoganlovells.com

Languages

English

Practices

Health

Government Relations and Public Affairs

Industries

Life Sciences and Health Care

Areas of focus

Legislation

Hospitals and Health Care Providers

Medical Devices

Assisted a medical device company in the reversal of Medicare non-coverage of artificial hearts, and secured an inpatient new technology add-on.

Helped multiple clients obtain Healthcare Common Procedure Coding System code for their products and prompt reimbursement for the products.

Assisted organ procurement organizations with their membership in the United Network for Organ Sharing and participation in the Medicare program.

Facilitated obtaining Medicare coverage of Investigation Device Exemption devices.

Represented hospital associations in a challenge to a Medicare outpatient hospital rule that resulted in a favorable administrative resolution.

Awards and rankings

- Healthcare (Nationwide): Recognised Practitioner, *Chambers USA*, 2017

Latest thinking and events

- News
 - U.S. House passes drug pricing legislation
- News
 - Expedited breakthrough device coverage, “reasonable and necessary” definition delayed until Dec. 15
- News
 - Ramping up the drug pricing debate: Dueling bills and paying for health care infrastructure
- News
 - CMS delays “reasonable and necessary” definition, expedited breakthrough device coverage process rule
- News
 - Life sciences and health care horizons 2021
- News
 - CMS finalizes “reasonable and necessary” definition, expedited breakthrough device coverage

Pharmaceuticals and Biotechnology
Cell, Tissue, and Gene Therapies

Education and admissions

Education

J.D., University of Pennsylvania Law School, 1991

B.A., Tufts University, 1987

Memberships

Member, American Bar Association

Member, National Health Lawyers Association

Bar admissions and qualifications

District of Columbia

Pennsylvania

process